% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • dr_geoffrey_allan dr_geoffrey_allan Jul 1, 2013 5:08 PM Flag

    Lazard has maintained buy rating

    Can't post the link but search web and you will find

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lazard Calls Insmed's Arikace 'Still Viable' Following Competitor Concern, Continues to See Massive Upside in Shares
      12:00p ET July 1, 2013 (Benzinga)
      Insmed (NASDAQ: INSM) shares are down more than 15 percent Monday morning amid a Phase 3 trial of Arikace which met a primary endpoint, but a company slideshow which revealed competitor Novartis's (NYSE: NVS) Tobi drug showed more favorable results.

      Lazard analyst Joshua Schimmer reiterated a Buy rating on Insmed following the downside. The analyst believes Arikace is "still viable" despite the concern and market reaction Monday.

      With shares of Insmed last trading at $10.16, Schimmer's $24 price target represents potential upside of about 136 percent.

11.83-0.05(-0.42%)May 27 4:00 PMEDT